'
The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
- Home Page
- What's New?
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- Research ADCs
- Research Apoptosis
- Research B cell
- Research BRAF
- Research HDIs
- Research HER Pathways
- Research MET
- Research VEGF
- Why is the VEGF ligand essential throughout tumor development?
- What are the strategies for inhibiting the VEGF pathway?
- What are the effects of direct VEGF ligand inhibition?
- Why is continued VEGF inhibition important?
- Why do tumors progress?
- The role of VEGF across tumor types
- Slide decks and videos
- Glossary
- Clinical Trials
- Resources
- Contact Us
Related Resources for this page:
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Future Directions
- Antibody-Drug conjugates
- VEGF expression in gastric cancer
- HER Signaling
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Glycoengineered Antibodies
- VEGF expression in gastric cancer
- HER Signaling
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Non-Antibody Biologics
- Apoptosis
- VEGF expression in gastric cancer
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Targeted Small Molecules
- Apoptosis
- VEGF expression in gastric cancer
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MAPK Signaling
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- PI3K/Akt/mTOR Signaling
- Slide decks and videos
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Traditional Monoclonal Antibodies
- B-cell Surface Proteins
- Glossary
- VEGF expression in gastric cancer
- HER Signaling
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- Angiogenic Signaling
- Slide decks and videos
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Antibody-Drug conjugates
Share
Summary of VEGF and angiogenesis in
Summary of VEGF and angiogenesis in
bladder cancer
The importance of vascular endothelial growth factor (VEGF) and angiogenesis in bladder cancer development is supported by a considerable, increasing base of clinical study. These studies have found that high VEGF expression is associated with progression in bladder cancer and can be useful as a prognostic marker. They have also ascertained that high levels of VEGF expression indicate poor prognosis, as they correspond with decreased relapse-free and disease-free survival.1-3
High levels of VEGF expression have also been shown to positively correlate with high microvessel density, a concurrent predictor of occurrence and progression of bladder cancer.4,5
References:
- 1.
- Crew JP, O'Brien T, Bradburn M, et al. Cancer Res. 1997;57:5281-5285. PMID: 9393750
- 2.
- Yang S, Wu X, Luo C, et al. World J Urol. 2010;28:473-478. PMID: 20593288
- 3.
- Bernardini S, Fauconnet S, Chabannes E, et al. J Urol. 2001;166:1275-1279. PMID: 11547057
- 4.
- Wang S, Xia T, Zhang Z, et al. Zhonghua Wai Ke Za Zhi. 2000;38:34-36. PMID: 11831983
- 5.
- Miyata Y, Kanda S, Ohba K, et al. Clin Cancer Res. 2006;12(3 Pt 1):800-806. PMID: 16467091